Quantum Biopharma Ltd QNTM

$3.82 -0.14 (-3.54%)

Valuation

Market cap
25,338,000
Revenue TTM
$0
Net income TTM
$-26,180,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
119,600
Avg volume
222,406
Day's range
$3.71 – $3.96
Shares out
6,399,000
Stochastic %K
37%
Beta
0.45
Analysts
Strong Sell
Price target
$21.75

Price

Company profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of de...

Show more

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
833 571 1811
Website
https://www.quantumbiopharma.com
Address
1 Adelaide Street East, Suite 801, Toronto, Canada

Latest news

Stocktwits

MM1968 Sep 30, 2:41 AM
$GNS good evening GNS investors. FUD accounts are swarming right now. Bringing up decades old conspiracies to defame the CEO and the company. These are paid criminal accounts that have never built anything in their lives. Every legal case in SDNY and FL is winning. Moe was advised by his counsel to stop posting on social media in June. Ritz went dark sooner because as an attorney he knew what he did and that it would come back. Genius has multiple paths now to proceed. 1) Investor suit will recoup 4/22 to 5/25 buys. I experienced this with Geron. 2) SDNY ICC confirmation, Ritz bogus employee claim will bring back 7.38M shares plus $10M . Will be interesting if personal assets are seized by SDNY or it rolls over to $750M RICO tab. 3) $750 FL RICO proceeded past dismissal. Schedule en route. 4) $MMTLP $NWBO $QNTM Harrington cases all feed into $GNS manipulation suit. Genius can increase stock price by: 1) Retiring/Canceling shares 2) ASX dual listing 3) Going private
1 replies
James23db Sep 29, 6:30 PM
$QNTM low volume takes it down 6%. always losing on these pump and dumps. 🤷🏻‍♂️ guess ill just hold and pray
0 replies
Mariahernand Sep 28, 8:59 PM
$QNTM basically flat today. After all the attention quantum names have been getting
1 replies
ZacksResearch Sep 28, 2:09 PM
🚀 $QNTM just cleared a major hurdle for Lucid-MS Quantum BioPharma received FDA approval of its IND application for Lucid-MS, clearing the way for the company's lead multiple sclerosis candidate to advance into Phase 2 testing. Key takeaways: • FDA IND approval allows Quantum BioPharma to move Lucid-MS into Phase 2 clinical testing • The candidate previously completed Phase 1, where it showed a favorable safety profile and was well tolerated • Quantum says Lucid-MS uses a different mechanism from most existing MS therapies • The next step is to begin patient recruitment and Phase 2 clinical testing • The milestone moves Lucid-MS from early-stage development toward testing for potential therapeutic benefit in MS Price target breakdown here 👇 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39726&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39726
1 replies
Rambler1111 Sep 28, 3:58 AM
$QNTM
0 replies
FickleFin Sep 25, 1:51 PM
$NCNA this will head back to ATL ... another shitco. NEVER INVEST IN BIOTECH $QNTM
0 replies
FickleFin Sep 25, 12:16 PM
$QNTM $GNS $GME READ THE FINE PRINT!!! Another bunk press release... "However, for a company still in the clinical stage of development, an FDA clearance represents significant forward momentum. Investors and patients alike will likely be watching for updates on site activation, enrollment progress and eventual trial data as Quantum BioPharma works to advance a treatment approach it believes is fundamentally different from what is currently available"
1 replies
FickleFin Sep 25, 12:12 PM
$QNTM $GME $GNS what a fucking joke. The new ceo of unbuzzd is ZAPPY!!! 😂😂😂😂 A psychadelic conceirge now runs UNBUZZD. Just board rotation... again. What a fucking shitco period.
0 replies